Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

2,3,6-Trisubstituted pyridine-containing M4 PAM shows selectivity and preclinical efficacy

Aug. 29, 2019

Vanderbilt University presents new muscarinic M4 receptor antagonists

Aug. 29, 2019

Aptinyx discovers NMDA receptor modulators

Aug. 29, 2019

European Commission approves Soliris for neuromyelitis optica spectrum disorder

Aug. 28, 2019

FDA approves Nourianz for Parkinson's disease

Aug. 28, 2019

IRLAB to prioritize L-dopa-induced dyskinesia indication in development of IRL-790

Aug. 28, 2019

Lilly discovers TRPA1 antagonists

Aug. 28, 2019

Conditional deletion of Talpid3 produces mouse model of Joubert syndrome

Aug. 28, 2019

FDA clears IND for long-acting injectable antipsychotic based on MedinCell technology

Aug. 28, 2019

New lysosomal acid glucosylceramidase inhibitors identified at Takeda

Aug. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...